Flow cytometry is an ideal method for multiparametric analysis of cells. However, it has traditionally been too slow to test large libraries of compounds during the drug discovery process.
Yet, recent technological advances have removed several process bottlenecks and helped flow cytometry gain widespread use in high-throughput screening (HTS).
This infographic presents recent key innovations that ensure reliable, high-throughput, automated flow cytometry workflows to enhance drug discovery.
Download this infographic to discover:
- How to increase sample processing speed
- The advantages of automation capabilities
- Strategies to optimize the analysis of high volumes of data
Optimizing Flow Cytometry for Screening and Drug Discovery
Sample processing speed Workforce Data analysis
Multiplexing capabilities
with five lasers and 30 detectors
24/7 with a single operator
using high-capacity fluidics tanks
100,000 events per sec
without data loss or
compromised resolution
Automate
Integrates with laboratory
robotics system via
a device-agnostic API
96-well plates in < 15 min
384-well plates in < 60 min
without data loss or compromised resolution
Discover a flow
cytometer built for
high-throughput
screening
Unlock the Power of High-Throughput Flow
Cytometry with the ZE5 Cell Analyzer
Visit: Bio-rad.com/ZE5
COMPOUND
LIBRARIES
High-throughput screening (HTS) is a key strategy in drug discovery, as it allows for rapid automated testing of large libraries of compounds to assess their effect on specific biological targets. While flow cytometry is ideal for multiparametric analysis of cells,
it has traditionally been too slow in processing large libraries to gain widespread use in HTS. However, recent technological advances have removed several process bottlenecks and turned flow cytometry into a powerful high-throughput tool that can be
used for many types of assays. This infographic presents recent key innovations – from sample loading through to data analysis – that ensure reliable, high-throughput, automated flow cytometry workflows.
The ZE5 Cell Analyzer is an innovative, versatile flow
cytometer that allows you to complete reliable, automated
high-throughput screening.
The first limiting factor of any HTS workflow is the speed at
which the instrument can process samples. Increasingly faster
flow cytometers can solve this thanks to:
High event rate: Cutting-edge
instruments can capture up to
100,000 events per second.
The cytometer must have an adequate
Application Programming Interface
(API) library to increase functionality.
Low maintenance and minimal
downtime: Reliable fluidics with
reversible pump and unclog features.
Advantages of automation include:
Avoid sample carryover: An integrated wash
station travels with the probe, cleaning it
thoroughly between each sample.
High multiplexing capabilities and
sample formats.
Rapid cycling through samples: Introducing air
spaces in the line without destabilizing flow allows
samples to be rapidly analyzed sequentially while
remaining recognizably distinct.
Instruments that allow the integration
of Laboratory Information Management
Systems (LIMS) can streamline the
process even further.
As sample processing becomes faster, prepping and loading
plates becomes the limiting factor. Flow cytometers with
automation capabilities can overcome this hurdle.
High volumes of data require new strategies for analysis and
interpretation. Data analysis represents a bottleneck due to:
Implementation of AI and machine learning techniques offers
promise in addressing these challenges and can already be
used for:
However, many challenges remain including the need for:
Continuous operation Improved reproducibility
Increased throughput Improved data integrity
• High dimensionality
• Large data sets
• Data heterogeneity
• Dimensional reduction (tSNE and UMAP)
• Automated cell population identification
• Sample classification to predict clinical or
biological outcomes
• More robust analysis of
heterogeneous data sets
• Better use and integration of
existing biological knowledge into
analysis
• Greater availability and
standardization of data
NEW DRUGS
120,000 –
100,000 –
80,000 –
60,000 –
40,000 –
20,000 –
0 –
0 20,000 40,000 60,000 80,000 100,000 120,000
– – – – – – –
Expected count, sec
Measured count, sec